Abstract 11504: Elevated Seismocardiography-Derived Chest Energy is Associated With Aortic Flow Abnormalities in Patients With Aortic Valve Disease

Abstract

Introduction: Aortic valve disease (AVD) can induce abnormal flow and elevated peak velocity (Vmax), which has known association with aortopathy and implications for intervention, and thus is a key metric in AVD management. Seismocardiogram (SCG) chest acceleration measurements have been shown indicative of AVD. This study investigated relations between SCG energy and established aortic flow measures. Hypothesis: We hypothesize that standard of care clinical Vmax measurements from echocardiography or MRI correlate with SCG chest acceleration energy metrics. Methods: Healthy controls and AVD patients received standard of care echo or MRI and a same day SCG measurement (image, A). Patients had tricuspid or bicuspid aortic valve (TAV, BAV) and were presenting for routine imaging to assess valve/flow function (image, B). Controls (no known cardiovascular disease) were prospectively recruited. Subjects gave informed consent with IRB approval. MRI included 4D flow (1.5T, 1-3mm³/30-40ms); echo included 2D Doppler imaging (1.7-3.3MHz, 12-40 FPS). Standardized ascending aorta (AAo) Vmax measurements were taken from MR or echo images. SCG energy was calculated by spectral decomposition. Results: Enrolment was 76 subjects: 52 controls (48±17.4y, 23 F), 24 patients (18 BAV, 6 TAV, 31±20.9y, 5 F). Patients had elevated peak velocities (227±103cm/s vs. 106±21cm/s, p<0.01) and elevated SCG energy (10.4±2.6dB vs. 8.3±1.4dB, p<0.01). A significant relationship between elevated AAo Vmax and increased SCG energy was observed (R=0.63, p<0.01) (image, C). Conclusions: Evaluation of SCG in context of AVD shows its potential utility to screen for valve mediated aortic flow changes. Correlation observed between SCG energy and peak velocities, a key metric for management of valve disease and aortopathy, indicates the relevance of SCG measurements in this context. These results show potential for use of SCG as simple, cost-effective front-line screening tool for AVD patients.